Harold J. Burstein
About
Harold J. Burstein is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Harold J. Burstein has authored 220 papers receiving a total of 19.1k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Oncology, 114 papers in Cancer Research and 72 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Harold J. Burstein's work include Breast Cancer Treatment Studies (102 papers), HER2/EGFR in Cancer Research (84 papers) and Cancer Treatment and Pharmacology (81 papers). Harold J. Burstein is often cited by papers focused on Breast Cancer Treatment Studies (102 papers), HER2/EGFR in Cancer Research (84 papers) and Cancer Treatment and Pharmacology (81 papers). Harold J. Burstein collaborates with scholars based in United States, Italy and Spain. Harold J. Burstein's co-authors include Eric P. Winer, Jane C. Weeks, Clifford A. Hudis, Jennifer J. Griggs, Hope S. Rugo, Antonio C. Wolff, Rebecca Gelman, Ann H. Partridge, Stephen B. Edge and Mark R. Somerfield and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.
In The Last Decade
Harold J. Burstein
214 papers receiving 18.6k citations
Hit Papers
Peers
Harold J. Burstein
Richard L. Theriault United States
Sandra M. Swain United States
Julie R. Gralow United States
Antonio C. Wolff United States
Karen A. Gelmon Canada
Roger A’Hern United Kingdom
Giuseppe Curigliano Italy
Adam Brufsky United States
George W. Sledge United States
Vicente Valero United States
Citations per year, relative to Harold J. Burstein Harold J. Burstein (= 1×)
peers
Richard L. Theriault
Countries citing papers authored by Harold J. Burstein
Since
Specialization
Citations
This map shows the geographic impact of Harold J. Burstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harold J. Burstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harold J. Burstein more than expected).
Fields of papers citing papers by Harold J. Burstein
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Harold J. Burstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harold J. Burstein. The network helps show where Harold J. Burstein may publish in the future.
Co-authorship network of co-authors of Harold J. Burstein
This figure shows the co-authorship network connecting the top 25 collaborators of Harold J. Burstein. A scholar is included among the top collaborators of Harold J. Burstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harold J. Burstein. Harold J. Burstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Burstein, Harold J., Giuseppe Curigliano, Michael Gnant, et al.. (2025). Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer. Annals of Oncology. 36(12). 1433–1446.
2.
Jeselsohn, Rinath, Jingxin Fu, Reshma Mahtani, et al.. (2024). Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer. Cancer Research. 84(9_Supplement). PS12–2.
3.
Garrido-Castro, Ana C., Se Eun Kim, Rita Nanda, et al.. (2024). SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.. Journal of Clinical Oncology. 42(17_suppl). LBA1004–LBA1004.
4.
Makhlin, Igor, Lesley Fallowfield, N. Lynn Henry, et al.. (2024). Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights. JCO Oncology Practice. 21(2). 140–144.
5.
Valenza, Carmine, Dario Trapani, Sibylle Loibl, et al.. (2024). Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response. Journal of Clinical Oncology. 42(20). 2372–2376.
6.
Trapani, Dario, Qingchun Jin, Caroline Block, et al.. (2023). Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO Oncology Practice. 19(8). 560–570.
7.
Burstein, Harold J., et al.. (2023). Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 41(18). 3423–3425.
8.
Sella, Tal, Yue Zheng, Nabihah Tayob, et al.. (2022). Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). npj Breast Cancer. 8(1). 127–127.
9.
Metzger, Otto, Anita Giobbie‐Hurder, Nancy U. Lin, et al.. (2020). A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. Breast Cancer Research and Treatment. 185(1). 135–144.
10.
Burstein, Harold J., Christina Lacchetti, Holly Anderson, et al.. (2018). Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. 37(5). 423–438.
11.
Rugo, Hope S., R. Bryan Rumble, & Harold J. Burstein. (2016). Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. Journal of Oncology Practice. 12(6). 583–587.
12.
Golshan, Mehra, Constance Cirrincione, William M. Sikov, et al.. (2016). Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Research and Treatment. 160(2). 297–304.
13.
Lin, Nancy U., Davinia Seah, Rebecca Gelman, et al.. (2013). A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 139(2). 403–410.
14.
Schwartz, Gordon F., Harry Bartelink, Harold J. Burstein, et al.. (2012). Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping. The Breast Journal. 18(4). 303–311.
15.
Seidman, Andrew D., Donald A. Berry, Constance Cirrincione, et al.. (2008). Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840. Journal of Clinical Oncology. 26(10). 1642–1649.
16.
Burstein, Harold J.. (2008). Updates in anti-HER2 combination therapy.. PubMed. 6(12). 873–4.
17.
Carlson, Robert W., Elizabeth Brown, Harold J. Burstein, et al.. (2006). NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Journal of the National Comprehensive Cancer Network. 4(S1). S–1.
18.
Carlson, Robert W., Susan J. Moench, M. Elizabeth H. Hammond, et al.. (2006). HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations. Journal of the National Comprehensive Cancer Network. 4(S3). S–1.
19.
Bendell, Johanna C., Susan M. Domchek, Harold J. Burstein, et al.. (2003). Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma. Cancer. 97(12). 2972–2977.
20.
Burstein, Harold J., Lyndsay N. Harris, Rebecca Gelman, et al.. (2002). Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study. Journal of Clinical Oncology. 21(1). 46–53.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Richard L. Theriault Breakdown of academic impact, for papers by Sandra M. Swain Breakdown of academic impact, for papers by Julie R. Gralow Breakdown of academic impact, for papers by Antonio C. Wolff Breakdown of academic impact, for papers by Karen A. Gelmon Breakdown of academic impact, for papers by Roger A’Hern Breakdown of academic impact, for papers by Giuseppe Curigliano Breakdown of academic impact, for papers by Adam Brufsky Breakdown of academic impact, for papers by George W. Sledge Breakdown of academic impact, for papers by Vicente Valero